Epigenetic ageing in 2025: what the Villanueva study adds to what we know
The science of epigenetic ageing has moved quickly. When the first generation of epigenetic clocks was developed in the early 2010s, the idea that a blood test could estimate biological age — and that this estimate would predict cancer risk independently of chronological age — was novel. By 2025, the field has matured substantially, with multiple generations of clock algorithms, larger validation datasets, and growing intervention evidence.
A 2025 study by Villanueva and colleagues, published in Aging, contributes meaningfully to this picture. It examines epigenetic age across a large sample, validating associations with health outcomes and exploring the lifestyle and environmental factors that drive epigenetic age acceleration — providing useful context for where the science currently stands and what it means in practice.
What epigenetic clocks measure — a brief recap
DNA methylation is a chemical modification to DNA — the addition of a methyl group to a cytosine base — that regulates gene expression without changing the underlying genetic sequence. Methylation patterns change systematically with age, and epigenetic clock algorithms exploit this regularity to estimate biological age from a blood or tissue sample.
The most widely used clocks include Horvath’s original pan-tissue clock (2013), PhenoAge (Levine et al., 2018), and GrimAge (Lu et al., 2019). GrimAge and PhenoAge are considered “second generation” clocks because they were trained on mortality and morbidity outcomes rather than chronological age alone, making them stronger predictors of health outcomes. The gap between biological age and chronological age is called epigenetic age acceleration — a positive value is associated with higher risk of age-related diseases including cancer.
Key findings relevant to cancer risk
Smoking emerged as one of the strongest drivers of epigenetic age acceleration — consistent with the broader literature. The effect is dose-dependent, and some acceleration appears reversible after cessation, though reversal is incomplete and takes years.
Physical inactivity was associated with accelerated epigenetic ageing, with regular physical activity associated with deceleration — consistent with the exercise and cancer survival evidence discussed in Posts 3, 32, and 33 of this series.
Diet quality was inversely associated with epigenetic age acceleration. Higher diet quality scores, reflecting greater adherence to plant-rich, low-processed-food dietary patterns, were associated with slower epigenetic ageing — consistent with the DAMA study findings (Post 37).
BMI and adiposity were associated with accelerated epigenetic ageing, particularly visceral adiposity. Adipose tissue is metabolically active, producing pro-inflammatory cytokines and oestrogens that drive epigenetic age acceleration.
Sleep duration and quality showed a U-shaped relationship — both short sleep (under six hours) and long sleep (over nine hours) were associated with greater epigenetic age acceleration than seven to eight hours.
Social and psychological factors — including chronic stress and social isolation — were associated with accelerated epigenetic ageing, providing further mechanistic grounding for the Cole 2011 findings on loneliness and gene expression discussed in Post 34.
What this means for the series as a whole
Each of the lifestyle factors associated with epigenetic age acceleration in the Villanueva data corresponds to a topic covered elsewhere in this series: smoking and alcohol (Posts 6 and 28), exercise (Posts 3, 32, and 33), diet quality (Posts 4, 25, 35, 36, and 37), sleep (Posts 7 and 15), stress and social connection (Posts 7, 17, and 34).
The consistent finding is that epigenetic age acceleration is not driven by any single factor — it is the cumulative product of multiple lifestyle exposures operating simultaneously. The most meaningful reductions come not from optimising one variable in isolation, but from improving the overall lifestyle profile across multiple domains. This is the scientific basis for the integrated approach to cancer-protective living that this series has been building towards.
How large are the effects
Smoking a pack per day for 20 years is associated with several years of epigenetic age acceleration. Regular vigorous exercise is associated with one to two years of deceleration compared to sedentary controls. Adherence to a Mediterranean dietary pattern (from the DAMA study) produces a significant but more modest reduction. The Fitzgerald multimodal protocol — diet, supplements, exercise, sleep, and stress management combined — reported a 3.23-year reduction over eight weeks in the men’s RCT.
These numbers are not directly comparable across studies (different clocks, different populations, different durations), but they convey a consistent message: lifestyle choices have real, measurable effects on biological age, and those effects accumulate over time.
The practical implications
Epigenetic age is not fixed. The Villanueva data, the DAMA trial, the Fitzgerald RCT, and the DIRECT PLUS study all point in the same direction: epigenetic age responds to lifestyle. It is a dynamic measure that shifts with behaviour, not a static reflection of irreversible damage.
Multiple domains matter. The most impactful approach addresses sleep, diet, exercise, stress, and social connection simultaneously. The effects are additive, and the cumulative impact across domains is substantially larger than any single intervention.
Commercial epigenetic age testing exists but should be interpreted carefully. Several companies offer direct-to-consumer biological age tests based on DNA methylation. The underlying science is legitimate, but specific clock algorithms, validation data, and precision vary. A single result is a snapshot — meaningful interpretation requires serial testing over time to detect change.
The absence of symptoms is not the absence of biological ageing. Epigenetic age acceleration is largely asymptomatic until it contributes to disease. This is precisely why monitoring the lifestyle behaviours that drive it matters: it provides an earlier window on processes that will not become clinically visible for years or decades.
What the evidence does not show
The lifestyle-epigenetic age associations in the Villanueva study are observational — causal claims require intervention data, which exists for some factors (exercise, diet) but not others. The study does not demonstrate that reducing epigenetic age acceleration reduces cancer incidence in a prospective trial. And the specific clock algorithms used in different studies are not always directly comparable, which complicates interpretation across the literature.
The bottom line
The Villanueva 2025 Aging study adds to a rapidly maturing literature on the lifestyle determinants of epigenetic age acceleration. Smoking, physical inactivity, poor diet quality, elevated BMI, disrupted sleep, chronic stress, and social isolation are all independently associated with faster biological ageing as measured by second-generation epigenetic clocks. These are the same lifestyle factors that the broader cancer prevention literature has identified as modifiable risk variables. The convergence of the epigenetic ageing literature with the cancer prevention literature is not coincidental — it reflects the fact that both bodies of evidence are measuring the same underlying biological processes. Slowing epigenetic ageing and reducing cancer risk are, in large part, the same project.
Scientific references
- Villanueva A, et al. Epigenetic ageing and lifestyle determinants. Aging. 2025. DOI: 10.18632/aging.206240
- Dugué P-A, et al. Epigenetic clock and risk of cancer. International Journal of Cancer. 2017. DOI: 10.1002/ijc.31189
- Fiorito G, et al. DAMA study: Mediterranean diet and epigenetic ageing. Aging Cell. 2021. DOI: 10.1111/acel.13439
- Fitzgerald KN, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging. 2021. DOI: 10.18632/aging.202913. Note: 2024 correction DOI: 10.18632/aging.205700
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
